Bone Biologics Ownership
| BBLG Stock | USD 1.31 0.06 4.80% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Bone |
Bone Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.85. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bone Biologics Corp recorded a loss per share of 1.46. The entity last dividend was issued on the 24th of July 2018. The firm had 1:8 split on the 20th of December 2023. Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2 people. For more info on Bone Biologics Corp please contact Jeffrey Frelick at 781 552 4452 or go to https://www.bonebiologics.com.Bone Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bone Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bone Biologics Corp backward and forwards among themselves. Bone Biologics' institutional investor refers to the entity that pools money to purchase Bone Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 33.7 K | Hrt Financial Llc | 2024-06-30 | 17.5 K | Tower Research Capital Llc | 2024-06-30 | 5.8 K | Mcmahon Financial Advisors, Llc | 2024-09-30 | 403 | Bank Of America Corp | 2024-06-30 | 9.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Bone Biologics Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bone Biologics Outstanding Bonds
Bone Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bone Biologics Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bone bonds can be classified according to their maturity, which is the date when Bone Biologics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.